Editas Medicine, Inc.EDITNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-2.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -211.40% |
| Q3 2025 | 22.21% |
| Q2 2025 | -39.15% |
| Q1 2025 | -45.29% |
| Q4 2024 | 2.04% |
| Q3 2024 | -9.76% |
| Q2 2024 | 11.42% |
| Q1 2024 | -30.42% |
| Q4 2023 | 1176.05% |
| Q3 2023 | -82.08% |
| Q2 2023 | -21.23% |
| Q1 2023 | -27.30% |
| Q4 2022 | 25.82% |
| Q3 2022 | -5.34% |
| Q2 2022 | 14.96% |
| Q1 2022 | 1.13% |
| Q4 2021 | 28.32% |
| Q3 2021 | -13.30% |
| Q2 2021 | -19.51% |
| Q1 2021 | -31.81% |
| Q4 2020 | 81.34% |
| Q3 2020 | 21.10% |
| Q2 2020 | -18.98% |
| Q1 2020 | -0.63% |
| Q4 2019 | 53.24% |
| Q3 2019 | -3.66% |
| Q2 2019 | 48.75% |
| Q1 2019 | -17.47% |
| Q4 2018 | 10.04% |
| Q3 2018 | -46.69% |
| Q2 2018 | 53.61% |
| Q1 2018 | -19.39% |
| Q4 2017 | 29.55% |
| Q3 2017 | 17.77% |
| Q2 2017 | -8.95% |
| Q1 2017 | -29.12% |
| Q4 2016 | 147.74% |
| Q3 2016 | 3.85% |
| Q2 2016 | 17.43% |
| Q1 2016 | 52.45% |